COPB2 and colorectal cancer: Our experimental data, comparing pancreatic and colorectal cancer cell lines with different KRAS genotypes after COPB2 knock down, implicate that this knock down has a higher negative impact on the number of living cells in the case of homozygous pancreatic KRAS mutated cells and heterozygous colorectal cells, with respect to the KRAS wild type cells (Figures 7 and 8).